First AD

Second AD

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss optimal management for adverse effects related to neratinib in HER2-positive early breast cancer. 

AE Management With Neratinib in HER2+ Early Breast Cancer

Breast Cancer

ELI-22-OSD1261 - /clinical/colorectal-cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

HER2+ Breast Cancer

SEA-22-OSD1249 - /clinical/her2-positive-neoadjuvant-care

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Evolving Adjuvant Treatments for HER2+ Early Breast Cancer

OncLive News Network®

University of Illinois Cancer Center

Cancer Centers

Partner

Cleveland Clinic

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss optimal management for adverse effects related to neratinib for patients with HER2-positive early breast cancer. 

Prognosis and Survival Outcomes for HER2+ Early Breast Cancer

Evolving and Current Standards of Care for HER2+ Early Breast Cancer

Unmet Needs in HER2+ Early Breast Cancer

Clinical Benefits With Neratinib in HER2+ Early Breast Cancer

Ongoing Research Efforts in HER2+ Early Breast Cancer